

BUSTA N. 1

3A. Scritto Generale: Quali sono le principali Tossicità da Immunoterapia?


3B. Scritto Specifica: Cosa si intende per Studio clinico randomizzato?

A handwritten signature in black ink, appearing to be 'G. L. S.', located in the bottom right quadrant of the page.A handwritten signature in black ink, appearing to be 'M. S.', located in the bottom right corner of the page.

BUSTA N. 2

1A. Scritto Generale: Descrivere brevemente le Fasi delle Sperimentazioni Cliniche (Fase I, II, III, IV)

1B. Scritto Specifica: Quali sono gli ENDPOINT principali esplorati negli studi di oncologia?

A handwritten signature in black ink, appearing to be 'Pau'.A handwritten signature in black ink, appearing to be 'Pau'.

2A. Scritto Generale: Il Team Multidisciplinare in oncologia: cosa si intende e da quali figure professionali è composto?

2B. Scritto Specifica: Descrivere brevemente cosa si intende per Studio di Fase IV, e relativi possibili *bias*

A handwritten signature in black ink, appearing to be 'G. L.' or similar, written in a cursive style.A handwritten signature in black ink, appearing to be 'L. M.' or similar, written in a cursive style.

**CONCORSO PUBBLICO, PER TITOLI ED ESAMI A TEMPO DETERMINATO PER 1 POSTO RICER. SANIT.,
CATEGORIA DS, LAUREATI IN MEDICINA E CHIRURGIA DA ASSEGNARE AL DIPARTIMENTO DI CLINICA E
RICERCA ONCOLOGICA DELL' ISTITUTO REGINA ELENA**

DOMANDE COLLOQUIO

Cosa sono i criteri RECIST in oncologia?

Definizione di Comprehensive Cancer Center





HHS Public Access

Author manuscript

Breast Cancer Res Treat. Author manuscript; available in PMC 2020 September 24.

Published in final edited form as:

Breast Cancer Res Treat. 2019 January ; 173(1): 37–48. doi:10.1007/s10549-018-4921-9.

Male breast cancer: a disease distinct from female breast cancer

Ayca Gucalp^a, Tiffany A. Traina^a, Joel R. Eisner^b, Joel S. Parker^{c,d}, Sara R. Selitsky^d, Ben H. Park^e, Anthony D. Elias^f, Edwina S. Baskin-Bey^b, Fatima Cardoso^g

^aMemorial Sloan Kettering Cancer Center, New York, NY, USA

^bInnocrin Pharmaceuticals Inc., Durham, NC, USA

^cDepartment of Genetics, University of North Carolina, Chapel Hill, NC, USA

^dLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA

^eJohns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

^fDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

^gBreast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal

Keywords

male breast cancer; androgen receptor; biomarkers; anti-androgen; endocrine therapy; androgen and estrogen biosynthesis inhibition

Introduction

Male breast cancer (BC) is rare, representing approximately 1% of cancers that occur in men and approximately 1% of all BCs worldwide [1–6]. Less than 0.2% of cancer-related deaths in men can be attributed to male BC [7, 8]. Because male BC occurs at a very low incidence, BC literature, research, clinical trials, and development of new treatment options primarily focus on female BC. Although knowledge about female BC can inform male BC diagnosis and treatment, molecular and clinicopathologic features differ between male and female BC. Biologic factors, such as sex differences, hormonal regulation, and response to treatment (both tolerability and activity), must be considered when defining this disease in men and deciding upon treatment options [8]. Currently, no standard of care (SOC) exists for male BC, and there is an unmet need for research and therapeutic options for this disease. This review summarizes current knowledge of male BC to date with a discussion of future treatment options for the disease.

Demographics of Male Breast Cancer

Almost 1% of all BCs occur in men. In 2018, about 2550 men will be diagnosed with BC in the US, and male BC will account for 480 deaths. In comparison, it is estimated that there

Contact information for corresponding author: Ayca Gucalp, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, Evelyn H. Lauder Breast Center, 300 East 66th Street, New York, NY 10065, Phone: 646-888-4536, Fax: 646-888-4917, gucalpa@mskcc.org.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



Domande Informatica

1. Cos'è il Provider
2. Cosa significa Login
3. Cos'è word
4. Cos'è la posta elettronica
5. Cos'è il backup
6. Definizione di account
7. Definizione di motore di ricerca
8. Definizione di browser
9. Definizione di software
10. Definizione di scanner
11. Definizione di hardware
12. Che cos'è Excel
13. Cosa significa zippare un documento
14. Che cos'è una USB
15. Definizione di file
16. La firma digitale
17. La PEC
18. Cos'è un data-base?
19. Che cosa comprende il pacchetto office?
20. A cosa serve il programma Power Point?
21. Per cosa vengono utilizzate le formule in Excel
22. Cosa indica l'estensione .xls?
23. Cosa indica l'estensione .doc?

